Ampio Pharmaceuticals Inc (AMPE) Upgraded at ValuEngine
Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Wednesday.
Ampio Pharmaceuticals (NYSEMKT:AMPE) traded up 2.0244% during midday trading on Wednesday, hitting $0.8366. The company had a trading volume of 302,396 shares. Ampio Pharmaceuticals has a 1-year low of $0.38 and a 1-year high of $1.14. The company has a 50 day moving average price of $0.61 and a 200 day moving average price of $0.62. The firm’s market capitalization is $57.08 million.
COPYRIGHT VIOLATION NOTICE: “Ampio Pharmaceuticals Inc (AMPE) Upgraded at ValuEngine” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/11/ampio-pharmaceuticals-inc-ampe-upgraded-at-valuengine.html.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Ampio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.